INBX
NASDAQ · Biotechnology
Inhibrx Biosciences Inc
$60.92
-3.95 (-6.09%)
Financial Highlights (FY 2026)
Revenue
171.9K
Net Income
1.46B
Gross Margin
—
Profit Margin
843,786.0%
Rev Growth
-69.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 56.7% | 56.7% |
| Operating Margin | 845,025.0% | 760,522.8% | -23.7% | -26.0% |
| Profit Margin | 843,786.0% | 801,596.7% | -30.0% | -23.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 171.9K | 568.5K | 384.43M | 347.35M |
| Gross Profit | — | — | 217.96M | 196.94M |
| Operating Income | 1.45B | 4.32B | -91,253,184 | -90,196,370 |
| Net Income | 1.46B | 4.33B | -115,444,062 | -82,575,244 |
| Gross Margin | — | — | 56.7% | 56.7% |
| Operating Margin | 845,025.0% | 760,522.8% | -23.7% | -26.0% |
| Profit Margin | 843,786.0% | 801,596.7% | -30.0% | -23.8% |
| Rev Growth | -69.8% | -69.8% | -5.8% | +11.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 85.85M | 85.10M |
| Total Equity | — | — | 832.96M | 791.72M |
| D/E Ratio | — | — | 0.10 | 0.11 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 1.46B | 4.59B | -155,644,267 | -144,289,075 |
| Free Cash Flow | — | — | -85,235,104 | -84,943,791 |